Highlights and Quick Summary
- Debt Growth for the quarter ending September 29, 2021 was -0.56 (a -4.35% decrease compared to previous quarter)
- Year-over-year quarterly Debt Growth increased by 27725.0%
- Annual Debt Growth for 2020 was -0.0 (a -100.0% decrease from previous year)
- Annual Debt Growth for 2019 was 219.67 (a -22302.01% decrease from previous year)
- Annual Debt Growth for 2014 was -0.99 (a 592.37% increase from previous year)
Visit stockrow.com/ANIK
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Debt Growth of Anika Therapeutics Inc.
Most recent Debt Growthof ANIK including historical data for past 10 years.Interactive Chart of Debt Growth of Anika Therapeutics Inc.
Anika Therapeutics Inc. Debt Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | -0.56 | -0.58 | -0.05 | – |
| 2020 | -0.0 | 1.21 | 1.35 | 0.05 | -0.0 |
| 2019 | 219.67 | 1.57 | 1.5 | 1.42 | 219.67 |
| 2014 | – | – | – | -0.99 | -0.99 |
| 2013 | – | -0.16 | -0.15 | -0.15 | – |
| 2012 | -0.14 | -0.14 | -0.13 | -0.13 | -0.14 |
| 2011 | -0.13 | -0.12 | -0.12 | -0.11 | -0.13 |
Business Profile of Anika Therapeutics Inc.
Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.